Table 1 Demographic and Clinical Data from Dose-Escalation Study Population Receiving Enteral Levetiracetam 40 mg/kg load and 30 mg/kg Q12 hourly (n = 7)
From: A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria
Characteristic | |
|---|---|
Gender (n, % male) | 3/7, 43% |
Age in months | Mean 54.3; median 53; range 26–81 |
Retinopathy positive (n, %) | 4/7, 57% |
Admission hypoglycemia* (n, %) | 0/7, 0% |
Admission lactate (mmol/L) | Mean 5.4; median 4.5; range 2.2–13.1 |
Admission hematocrit (% packed cell volume) | Mean 22.2; median 20.7; range 13.0–33.6 |
Parasitemia (parasite per μl) | Geometric mean 73,700; median 70,000; range 25,920-374,460 |
Platelets (per μl) | Mean 123,000; median 80,000; range 47,000-259,000 |
Coma resolution time (hours) | Mean 35.2; median 32.8; range 6.5–78.0 |